Gensight Biologics (XPAR:SIGHT) Debt-to-Equity : -0.60 (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Gensight Biologics Debt-to-Equity?

Gensight Biologics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €17.38 Mil. Gensight Biologics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €1.05 Mil. Gensight Biologics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was €-30.67 Mil. Gensight Biologics's debt to equity for the quarter that ended in Dec. 2023 was -0.60.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Gensight Biologics's Debt-to-Equity or its related term are showing as below:

XPAR:SIGHT' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.82 Med: 0.68 Max: 1.23
Current: -0.6

During the past 12 years, the highest Debt-to-Equity Ratio of Gensight Biologics was 1.23. The lowest was -0.82. And the median was 0.68.

XPAR:SIGHT's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.14 vs XPAR:SIGHT: -0.60

Gensight Biologics Debt-to-Equity Historical Data

The historical data trend for Gensight Biologics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gensight Biologics Debt-to-Equity Chart

Gensight Biologics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.68

1.23

0.79

-0.82

-0.60

Gensight Biologics Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.79	3.44	-0.82	-0.59	-0.60

Competitive Comparison of Gensight Biologics's Debt-to-Equity

For the Biotechnology subindustry, Gensight Biologics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Gensight Biologics's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gensight Biologics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Gensight Biologics's Debt-to-Equity falls into.

Gensight Biologics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Gensight Biologics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(17.38	+	1.048)	/	-30.668
	=	-0.60

Gensight Biologics's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(17.38	+	1.048)	/	-30.668
	=	-0.60

Gensight Biologics (XPAR:SIGHT) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Gensight Biologics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Gensight Biologics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Gensight Biologics (XPAR:SIGHT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gensight Biologics SA (XPAR:SIGHT) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

GSGTF:USA G49N:Germany

Address

74,rue du Faubourg Saint-Antoine, Paris, FRA, 75012

Website

https://www.gensight-biologics.com

Gensight Biologics SA is a clinical-stage biotechnology group discovering and developing novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system. The company's pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence, and Optogenetics, to help preserve or restore vision in patients suffering from severe degenerative retinal diseases. The group focus is on ophthalmology where it develops product candidates to restore eyesight to patients suffering from retinal diseases. The product candidate, LUMEVOQ, was developed using the MTS technology platform and is designed to treat LHON by restoring the function of retinal diseases resulting from mutations.

Gensight Biologics (XPAR:SIGHT) Headlines

No Headlines